CBAC-01 is under clinical development by CHA Biotech and currently in Phase II for Stroke. According to GlobalData, Phase II drugs for Stroke have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBAC-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CBAC-01 overview

CordSTEM-ST is under development for the treatment of stroke. Stem cells obtained from embryos and foetus are thought to be best because they are more likely to survive transplantation than those obtained from children or adults. It is administered intravenously. It acts by targeting interleukin 1 receptor (IL1R). It also comprises of enhanced umbilical cord adherent stem cells. It was also under development for the treatment of foot ulcers and cerebral infarction. 

CHA Biotech overview

CHA Biotech, formerly CHA Bio & Diostech, is a biotechnology company that offers cell therapeutics development, bio insurance, cord blood, and stem cell banking solutions. Its R&D pipeline provides research in the therapeutic areas of age-related macular degeneration, intermittent claudication, stroke, Stargardt degeneration, Alzheimer’s disease, disk degeneration and others. CHA Biotech offers a bio-medical complex system that helps in managing cord blood collection, treatment, and transplantation; and also conducts ongoing research on cord blood-based therapeutics for treating incurable diseases using adult stem cells, embryonic stem cells and immune cells. The company provides hospital IT management services across Japan. CHA Biotech is headquartered in Seongnam, Gyeonggido, South Korea.

For a complete picture of CBAC-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.